(Q38208727)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24788803%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

title

Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24788803%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24788803%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Christos Rizos

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24788803%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Moses Elisaf

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24788803%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

author name string

Michael S Kostapanos

1

1 reference

31 August 2017

Christos V Rizos

2

1 reference

31 August 2017

Moses S Elisaf

3

1 reference

31 August 2017

1 July 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24788803%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24788803%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

volume

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24788803%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24788803%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

page(s)

481-500

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24788803%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s40264-014-0169-4

17 March 2020

exact match

0 references

cites work

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

21 January 2018

Safety of rosuvastatin

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

JUPITER and satellites: Clinical implications of the JUPITER study and its secondary analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating R

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Low concentration of serum total cholesterol is associated with multifocal signal loss lesions on gradient-echo magnetic resonance imaging: analysis of risk factors for multifocal signal loss lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuv

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Use of multiple international healthcare databases for the detection of rare drug-associated outcomes: a pharmacoepidemiological programme comparing rosuvastatin with other marketed statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Liver enzymes: potential cardiovascular risk markers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Association between serum gamma-glutamyltransferase and acute ischemic nonembolic stroke in elderly subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Pleiotropic effects of rosuvastatin on the glucose metabolism and the subcutaneous and visceral adipose tissue behavior in C57Bl/6 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Rosuvastatin may modulate insulin signaling and inhibit atherogenesis beyond its plasma cholesterol-lowering effect in insulin-resistant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Molecular mechanisms involved in NAFLD progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Different anti-HCV profiles of statins and their potential for combination therapy with interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Characterization of the hepatitis C virus RNA replication complex associated with lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Incidence of statin hepatotoxicity in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Microalbuminuria: a neglected cardiovascular risk factor in non-diabetic individuals?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Lipid nephrotoxicity: new concept for an old disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Dyslipidemia associated with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Statin pleiotropy against renal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Rosuvastatin-induced arrest in progression of renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Dose-dependent effect of rosuvastatin treatment on urinary protein excretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Longitudinal assessment of estimated glomerular filtration rate in apparently healthy adults: a post hoc analysis from the JUPITER study (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evalu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Rosuvastatin in diabetic hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Novel cardiovascular risk factors in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

An overview of the extra-lipid effects of rosuvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Protective effects of rosuvastatin in experimental renal failure rats via improved endothelial function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Angiotensin-II and rosuvastatin influence matrix remodeling in human mesangial cells via metalloproteinase modulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Rosuvastatin inhibits pressure-induced fibrotic responses via the expression regulation of prostacyclin and prostaglandin E2 in rat renal tubular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Rosuvastatin attenuates inflammation, apoptosis and fibrosis in a rat model of cyclosporine-induced nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Rosuvastatin prevents proteinuria and renal inflammation in nitric oxide-deficient rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Rosuvastatin improves endothelial function in db/db mice: role of angiotensin II type 1 receptors and oxidative stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Renoprotective effect of rosuvastatin in DOCA-salt hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Pharmacokinetic and pharmacodynamic profile of rosuvastatin in patients with end-stage renal disease on chronic haemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Statins of high versus low cholesterol-lowering efficacy and the development of severe renal failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Insulin resistance, oxidative stress, and podocyte injury: role of rosuvastatin modulation of filtration barrier injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI-Heart Failure trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

An overview of statin-associated proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

How does proteinuria cause progressive renal damage?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Statins inhibit aminoglycoside accumulation and cytotoxicity to renal proximal tubule cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Risk factors for cardiovascular mortality and morbidity: the WHO Mutinational Study of Vascular Disease in Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Impaired fasting glucose and risk of cardiovascular disease in Korean men and women: the Korean Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Statin therapy and risk of developing type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Do statins beneficially or adversely affect glucose homeostasis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Statins: beneficial or adverse for glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Risk of incident diabetes among patients treated with statins: population based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Differential impact of statin on new-onset diabetes in different age groups: a population-based case-control study in women from an asian country

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Statins and risk of treated incident diabetes in a primary care population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Effect of hypolipidemic treatment on glycemic profile in patients with mixed dyslipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Rosuvastatin does not affect fasting glucose, insulin resistance, or adiponectin in patients with mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Colesevelam plus rosuvastatin 5 mg/day versus rosuvastatin 10 mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes---the CORALL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0169-4

Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program

21 January 2018

1 reference

12 December 2020

Differential effect of statins on diabetic nephropathy in db/db mice.

1 reference

12 December 2020

Coronary atherosclerosis can regress with very intensive statin therapy.

1 reference

12 December 2020

Cardiovascular morbidity and mortality associated with the metabolic syndrome

1 reference

12 December 2020

Combined vascular effects of HMG-CoA reductase inhibitor and angiotensin receptor blocker in non-diabetic patients undergoing peritoneal dialysis

1 reference

12 December 2020

25-hydroxyvitamin D insufficiency is associated with impaired renal endothelial function and both are improved with rosuvastatin treatment

1 reference

12 December 2020

High-dose atorvastatin after stroke or transient ischemic attack

1 reference

12 December 2020

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

1 reference

12 December 2020

Rosuvastatin in patients with elevated C-reactive protein.

1 reference

12 December 2020

Editorial: reducing cardiovascular risk: is low-density lipoprotein-cholesterol (LDL-C) lowering enough?

1 reference

12 December 2020

Subcutaneous fatness and mortality

1 reference

12 December 2020

Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein- and complement-dependent interstitial inflammation in experimental renal disease

1 reference

12 December 2020

Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate

1 reference

12 December 2020

Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property

1 reference

12 December 2020

Pharmacokinetics of rosuvastatin in patients with end-stage kidney disease undergoing peritoneal dialysis.

1 reference

12 December 2020

Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels

1 reference

12 December 2020

A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia

1 reference

12 December 2020

Nonalcoholic fatty liver disease and its association with cardiovascular disease.

1 reference

12 December 2020

Effects of statins on renal function

1 reference

12 December 2020

Effects of rosuvastatin and atorvastatin on renal function: meta-analysis

1 reference

12 December 2020

Efficacy analysis of the lipid-lowering and renoprotective effects of rosuvastatin in patients with chronic kidney disease

1 reference

12 December 2020

Impact of intensive lipid lowering on lipid profiles over time and tolerability in stable coronary artery disease: insights from a subanalysis of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in

1 reference

12 December 2020

Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-cIN trial).

1 reference

12 December 2020

Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial

1 reference

12 December 2020

Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program

1 reference

12 December 2020

Intravascular ultrasound analysis of reduction in progression of coronary narrowing by treatment with pravastatin

1 reference

12 December 2020

A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients

1 reference

12 December 2020

Rosuvastatin beneficially alters the glomerular structure of kidneys from spontaneously hypertensive rats (SHRs)

1 reference

12 December 2020

In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation.

1 reference

12 December 2020

Lipoprotein(a) concentration in patients with chronic active hepatitis C before and after interferon treatment

1 reference

12 December 2020

Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy

1 reference

12 December 2020

Rosuvastatin increases alpha-1 microglobulin urinary excretion in patients with primary dyslipidemia

1 reference

12 December 2020

Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial)

1 reference

12 December 2020

Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with α-interferon and ribavirin: Rosuvastatin reduces NAFLD in HCV patients.

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD).

1 reference

12 December 2020

Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study

1 reference

12 December 2020

Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study)

1 reference

12 December 2020

Regression of atherosclerosis. Does it occur and does it have clinical meaning?

1 reference

12 December 2020

10.1007/S40264-014-0169-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24788803%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

17 March 2020

1014189623

0 references

Fatcat ID

release_xmmairjfm5cglf226ttjohgtoe

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xmmairjfm5cglf226ttjohgtoe

24 November 2022

mapped directly with Wikidata item

1 reference